Comparative Effectiveness of Anti-Hyperlipidemic Drugs Monotherapy in Primary Prevention of Cardiovascular Disease
Atorvastatin and pravastatin users had higher long-term rates of cardiovascular events compared to simvastatin monotherapy in primary prevention, the difference may be attributed to the confounding by severity, but also possibly due to differences in drug mechanisms or patient response. These findings could influence current guideline recommendations, suggesting a potential preference for simvastatin in primary prevention, underscoring the need for further research to explore long-term impacts and underlying mechanisms, especially in diverse populations.
Authors
- Stijn de Vos (ORCID: https://orcid.org/0000-0001-6965-4959)
- Xuechun Li (ORCID: https://orcid.org/0000-0003-2175-8307)
- Sumaira Mubarik (ORCID: https://orcid.org/0000-0001-6041-1061)
- Maarten J. Bijlsma (ORCID: https://orcid.org/0000-0002-7330-6006)
- Catharina C. M. Schuiling‐Veninga (ORCID: https://orcid.org/0000-0002-8527-2608)
- Eelko Hak (ORCID: https://orcid.org/0000-0003-0849-7210)
- Dennis Steenhuis (ORCID: https://orcid.org/0000-0003-0190-336X)
- Jens Bos (ORCID: https://orcid.org/0000-0001-9209-7564)
Institutions
- University of Groningen (NL)
- Max Planck Institute for Demographic Research (DE)
Publication Details
- Journal
- International Journal of General Medicine
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/ijgm.s479120
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.15
Funders
- China Scholarship Council